Atara Biotherapeutics (ATRA) Stock Price
Atara Biotherapeutics Price
Over the last 5 years Atara Biotherapeutics grew revenue by 102.4% annually, reaching 120.77 M USD. For Atara Biotherapeutics, the net margin of 27.1% is up versus -1,672.3% a few years ago. The consensus 12-month price target for Atara Biotherapeutics is 13.00 USD, about 62.3% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus.
Atara Biotherapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Atara Biotherapeutics business model & stock analysis
Frequently asked questions about Atara Biotherapeutics
Analysts currently set an average price target of 13.00 USD for the Atara Biotherapeutics stock (median: 13.00 USD), implying +62.3 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Atara Biotherapeutics stock: 8 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Atara Biotherapeutics to generate revenue of 2.85 M USD and earnings per share of -0.39 USD.
Converted at the current exchange rate, the Atara Biotherapeutics share trades at 7.18 EUR (8.01 USD).
The Atara Biotherapeutics share (ATRA) is listed on 7 stock exchanges, including: NASDAQ (ATRA), London (0HIY.L), SIX (Zürich) (AT2.SW), Frankfurt (AT2.F), München (AT2.MU), Düsseldorf (AT2.DU).
The expected revenue of Atara Biotherapeutics is 2.85 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Atara Biotherapeutics is -4.98 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Atara Biotherapeutics is currently -20.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Atara Biotherapeutics stock.
The price-to-sales ratio (P/S) of Atara Biotherapeutics is currently 35.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Atara Biotherapeutics stock.
The Eulerpool Quality Score for Atara Biotherapeutics is 6/10.
The ISIN of Atara Biotherapeutics is US0465132068. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Atara Biotherapeutics is A1166A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Atara Biotherapeutics is ATRA. The ticker symbol is used to trade Atara Biotherapeutics shares on the stock exchange.
Atara Biotherapeutics stock
Atara Biotherapeutics Peer Group
Atara Biotherapeutics Ticker
All fundamentals and in-depth analysis of Atara Biotherapeutics
Our stock analysis for Atara Biotherapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atara Biotherapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.